Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Yukio Kobayashi, MD DSc, Zachary F. Zimmerman, Iekuni Oh, MD PhD, Yoshinobu Maeda, MD PhD, Hironobu Minami, MD PhD, Toshihiro Miyamoto, MD PhD, Toru Sakura, PhD MD, Hiroatsu Iida, MD PhD, Yuqi Chen, PhD, Hitoshi Kiyoi, MD PhD

Blood (2018) 132 (Supplement 1): 5167.

https://doi.org/10.1182/blood-2018-99-112584

Published: 2018

Journal Articles

Nonacog Beta Pegol for Prophylactic Treatment of Children with Hemophilia B: Up to 3.5-Year Data from the Paradigm™5 Clinical Trial

Susan Kearney, MD, Elena Santagostino, Manuel Carcao, MD, Faraizah Abdul Karim, MD, Masashi Taki, MD PhD, Meng Yao Lu, MD, May-Lill Garly, MD PhD, Marek Zak, MD PhD

Blood (2017) 130 (Supplement 1): 1092.

https://doi.org/10.1182/blood.V130.Suppl_1.1092.1092

Published: 2017

Journal Articles

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

Guy Young, Robert F. Sidonio, Ri Liesner, Johannes Oldenburg, Tiffany Chang, Marianne Uguen, Christophe Dhalluin, Christophe Schmitt, Gallia G. Levy, Midori Shima, MDPhD, Johnny Mahlangu

Blood (2017) 130 (Supplement 1): 85.

https://doi.org/10.1182/blood.V130.Suppl_1.85.85

Published: 2017

Journal Articles

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Pallawi Torka, MD, Seema Bhat, Kelvin P. Lee, MD, Alan Hutson, Jenna Nichols, Angela Kader, Cory Mavis, MSc, AnneMarie W Block, Sheila N. J. Sait, PhD, Bora E Baysal, MD PhD, Fadi Habib, MD, Vishala T. Neppalli, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2017) 130 (Supplement 1): 2822.

https://doi.org/10.1182/blood.V130.Suppl_1.2822.2822

Published: 2017

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Andres Forero-Torres, MD, Kathryn S. Kolibaba, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Calvin Lee, Jeff Sharman, MD

Blood (2016) 128 (22): 1856.

https://doi.org/10.1182/blood.V128.22.1856.1856

Published: 2016

Journal Articles

ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study

Tomoki Naoe, MD PhD, Toru Sakura, MD PhD, Yukio Kobayashi, MD PhD, Kensuke Usuki, MDPhD, Toshihiro Miyamoto, MD PhD, Hiroatsu Iida, MD PhD, Satoshi Morita, PhD, Erkut Bahceci, MD, Masahito Kaneko, RPh, Shunsuke Yamada, M.Eng, Shigeru Takeshita, MSc, Shuichi Miyawaki, MDPhD

Blood (2015) 126 (23): 1320.

https://doi.org/10.1182/blood.V126.23.1320.1320

Published: 2015

Journal Articles

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Basem M. William, MD, Marcos de Lima, MD, Betul Oran, MD, Richard Champlin, MD, Esperanza B Papadopoulos, MD, Sergio Giralt, MD, Bart L. Scott, MD, Joel Hetzer, PhD, Xiwei Wang, PhD, Eric Laille, MS, Barry S. Skikne, MD, Charles Craddock, MDPhD

Blood (2014) 124 (21): 990.

https://doi.org/10.1182/blood.V124.21.990.990

Published: 2014

Journal Articles

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Michael Mauro, MD, Jerald Radich, MD, Jorge E. Cortes, MD, Shaker Dakhil, MD, Christopher Keir, MD, Sandy Yi, Martha Wadleigh, MD, Vivian G. Oehler, MD, Thomas Ervin, MD, Stuart Goldberg, MD, Michael Savona, MD, FACP

Blood (2013) 122 (21): 4015.

https://doi.org/10.1182/blood.V122.21.4015.4015

Published: 2013

Journal Articles

Nonacog Alfa: Analysis Of Safety Data From 6 Prospective Clinical Studies In Different Patient Populations With Hemophilia B Treated With Different Therapeutic Modalities

Pablo Rendo, MD, Lynne Smith, MBA, Lee Hsiao-Yu, Frank E. Shafer, MD

Blood (2013) 122 (21): 3604.

https://doi.org/10.1182/blood.V122.21.3604.3604

Published: 2013

Journal Articles

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

Razelle Kurzrock, MD, Peter M. Voorhees, MD, Corey Casper, MD, Richard R. Furman, MD, Luis Fayad, MD, Sagar Lonial, MD, Hossein Borghaei, DO, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Saad Usmani, MD, FACP, Helgi van de Velde, MD, PhD, Xiang Qin, PhD, Ming Qi, MD, PhD, Mark J. Cornfeld, MD, MPH, Frits van Rhee, MD, PhD

Blood (2011) 118 (21): 3959.

https://doi.org/10.1182/blood.V118.21.3959.3959

Published: 2011

Journal Articles

Central Venous Access Device-Related Infections in Hemophilia.

Janna M. Journeycake, MD, Don Brambilla, PhD, Margaret V. Ragni, MD, MPH

Blood (2005) 106 (11): 3216.

https://doi.org/10.1182/blood.V106.11.3216.3216

Published: 2005

NARROW

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Nonacog Beta Pegol for Prophylactic Treatment of Children with Hemophilia B: Up to 3.5-Year Data from the Paradigm™5 Clinical Trial

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

A Phase 1/2 Study of Carfilzomib Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide (C-RICE) in Patients with Transplant-Eligible, Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Single-Arm, Open-Label, Multicenter Study Of Deep Molecular Response (MR 4.5 ) With Nilotinib In Adult Patients (pts) With Newly Diagnosed Philadelphia Chromosome–Positive Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTnext Study Update

Nonacog Alfa: Analysis Of Safety Data From 6 Prospective Clinical Studies In Different Patient Populations With Hemophilia B Treated With Different Therapeutic Modalities

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

Central Venous Access Device-Related Infections in Hemophilia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only